5 Einträge gefunden

1. Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial

   1. Gaidzik, Verena I
   2. Paschka, Peter
   3. Schlenk, Richard F
   4. Weber, Daniela
   5. Fröhling, Stefan
   6. Krämer, Alwin
   7. Wäsch, Ralph

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin

   1. Teich, Katrin
   2. Krzykalla, Julia
   3. Kapp-Schwoerer, Silke
   4. Gaidzik, Verena I
   5. Schlenk, Richard F
   6. Paschka, Peter
   7. Weber, Daniela

   2021 - Forschungsinformationssystem des UKE
3. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

   1. Schlenk, Richard F
   2. Paschka, Peter
   3. Krzykalla, Julia
   4. Weber, Daniela
   5. Kapp-Schwoerer, Silke
   6. Gaidzik, Verena I
   7. Leis, Claudia

   2020 - Forschungsinformationssystem des UKE
4. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)

   1. Krauter, Jürgen
   2. Fiedler, Walter
   3. Schlenk, Richard F
   4. Paschka, Peter
   5. Thol, Felicitas
   6. Lübbert, Michael
   7. Wattad, Mohammed

   2018 - Forschungsinformationssystem des UKE
5. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial

   1. Paschka, Peter
   2. Schlenk, Richard F
   3. Weber, Daniela
   4. Benner, Axel
   5. Bullinger, Lars
   6. Heuser, Michael
   7. Gaidzik, Verena I

   2018 - Forschungsinformationssystem des UKE